A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome
NCT06684847 · Unity Phase 3Active, not recruiting
- Lead sponsor
- argenx (Industry)
- Enrollment
- 631 (actual)
- Start date
- 15 Jan 2025
- Primary completion
- Jul 2027 (estimated)
- Study completion
- 1 Jul 2028
- Last update posted
- 16 Apr 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Quadruple
- Arms
- 3
Interventions
- Efgartigimod PH20 SC Biological
- Placebo PH20 SC Other
Conditions and primary outcome
- Primary Sjogrens Disease
Primary outcome
Change from baseline in clinESSDAI score at week 48 (Up to 48 weeks)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06684847.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06684847 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.